logo
Bikes line up for Originals Ashburton motorcycle show

Bikes line up for Originals Ashburton motorcycle show

Willie Little and his one-of-a-kind 1996 Harley Davidson sporty chopper. PHOTO: TONI WILLIAMS
Willie Little took a 1996 Harley-Davidson Sportster and blinged it up with chrome.
It has a six inch oversized springer front end, been lowered an inch at the back and a customised sissy bar.
It is one of the toys, he said. Little, an engineer, did the work himself during Covid lockdown.
He bought the 1200cc sportster in 2019 for $5000 and imported parts from the United States.
Then Covid hit, giving him time to work on his machine.
About 40 motorbikes were on show at the recent Originals Ashburton motorcycle show and shine in the Ashburton RSA. Photo: Supplied
He stripped it all back and replaced the front, lowered it at the rear and handcrafted his own sissy bar.
Replaced the belt with a chain, put in a new exhaust, custom chromes and paint work.
Then he added a small 1950s-style peanut tank which holds about 3.5 litres of fuel.
"Enough to get you to the pub and back," he said.
The motorbike was on show at the recent Originals Ashburton motorcycle show and shine at the Ashburton RSA.
Photo: Supplied
There were about 40 bikes of all makes and models inside and outside the event ranging in ages from 1953 to 2025.
Little finally finished the motorcycle in time for last year's annual November bike show.
In keeping with his Harley-Davidson preference, his next project is to rebuild a Pan America.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview
2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview

USA Today

time23 minutes ago

  • USA Today

2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview

2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview Carson Branstine (No. 231 ranking) will take on Elena-Gabriela Ruse (No. 80) in the Round of 16 of the Libema Open on Thursday, June 12. Ruse is the favorite against Branstine for this match, with -275 odds against the the underdog's +270. Tennis odds courtesy of BetMGM Sportsbook. Odds updated Wednesday at 6:35 PM ET. For a full list of sports betting odds, access USA TODAY Sports Betting Scores Odds Hub. Carson Branstine vs. Elena-Gabriela Ruse matchup info Tournament: Libema Open Libema Open Round: Round of 16 Round of 16 Date: Thursday, June 12 Thursday, June 12 Court Surface: Grass Watch the Tennis Channel and more sports on Fubo! Branstine vs. Ruse Prediction Based on the implied probility from the moneyline, Branstine has a 73.3% to win. Branstine vs. Ruse Betting Odds Branstine vs. Ruse matchup performance & stats

Elon Musk's favorability among Republicans dropped 16 points since March, Quinnipiac says
Elon Musk's favorability among Republicans dropped 16 points since March, Quinnipiac says

CNBC

time23 minutes ago

  • CNBC

Elon Musk's favorability among Republicans dropped 16 points since March, Quinnipiac says

Elon Musk's official role in the Trump administration recently came to an end. Many Republicans won't be sad to see less of him, according to the results of Quinnipiac University's latest public opinion survey. While a majority of Republicans still hold a favorable view of Musk, the number fell to 62% in the poll out Wednesday, down from 78% in March, Quinnipiac said. Overall, the Quinnipiac poll found that 30% of self-identified voters surveyed in the U.S. hold a favorable opinion of Musk, according to polling from June 5 to June 9. Republican and Democratic voters remain deeply divided in their views of the world's richest man, who contributed nearly $300 million to propel President Donald Trump back to the White House. Only 3% of Democrats surveyed said they held a favorable of view of the Tesla CEO, who was once seen as an environmental leader appealing to liberal values. Musk didn't respond to a request for comment. Musk and Trump had a very public falling out last week that started with Musk's disapproval of the president's spending bill and escalated into an all-out war of words that played out on social media. Musk said on Wednesday that he regretted some of the posts he made about Trump last week, adding that "they went too far." Even with a slide in his favorability, Musk is still popular among Republicans after his time running the Department of Government Efficiency (DOGE), an effort to dramatically slash the size of the federal government. Among the Republican respondents to the early June poll, 80% rated Musk and DOGE's work as either excellent or good, while 13% said it was either not so good or poor. In the March poll, 82% of Republicans surveyed said they thought Musk and DOGE were helping the country. Read the full survey results here.

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results

Yahoo

time23 minutes ago

  • Yahoo

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store